NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common Stock
NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common Stock
NPS Pharmaceuticals, Inc.Susan M. Mesco, (908)450-5516
Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration
Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration May 20, 2013 LEXINGTON, Mass.--(BUSINESS WIRE)--...
Karyopharm Therapeutics Raises $48.2 Million in Series B Financing
NATICK, May 20, 2013 (GLOBE NEWSWIRE via COMTEX) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced that it has raised $48.2 million in a...
STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference
Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference
CytRx Issues Letter to Stockholders Providing Business Update
- Provides Detailed Roadmap for Oncology Drug Development Programs -
CytRx Issues Letter to Stockholders Providing Business Update
OvaScience Co-Founder Recognized in Boston Globe 100’s “The Innovators” Feature
Company also named among Boston’s 50 on Fire
OvaScience Co-Founder Recognized in 100’s “The Innovators” Feature
XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients SANTA CLARA, Calif., May 20, 2013 (BUSINESS WIRE) -- XenoPort, Inc. XNPT...
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) Solithromycin demonstrated enhanced...
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll...
Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
NEW YORK, May 20, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc....
Elan Announces Transactions: Decisively Transforming the Company
Elan Announces Transactions: Decisively Transforming the Company Proposed Transactions offer shareholders highly unique investment and asset proposition Acquisition of AOP Orphan – a...
Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
<0> Acorda TherapeuticsJeff Macdonald, 914-326-5232 </0>
eFFECTOR Therapeutics Raises $45 Million in Series A Financing
eFFECTOR Therapeutics Raises $45 Million in Series A Financing Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer San Diego, CA – May 20, 2013 –...
Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech SAN JOSE, Calif., May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce...
Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
Bagsværd, Denmark, – Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor...
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease Galapagos to fund and complete Phase 2...
Biologix Hair Inc. Appoints Dr. Michael Stocker Director and CEO; J. Gregory Wilson Appointed CFO
Biologix Hair Inc. Appoints Dr. Michael Stocker Director and CEO; J. Gregory Wilson Appointed CFO 5/15/2013 10:46:58 AM Staying up-to-date has never been simpler. Sign up for the free GenePool...
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team 0 0 0 17 May 15, 2013 06:00 | Source: Achillion Pharmaceuticals, Inc. NEW HAVEN, Conn., May 15,...
Harvard Bioscience Inc. (HBIO) Announces Retirement of CEO and Appointment of Interim CEO
Harvard Bioscience Inc. (HBIO) Announces Retirement of CEO and Appointment of Interim CEO Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Harvard...
